Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
Associations between the levels of estradiol-, progesterone-, and testosterone-sensitive mirnas and main clinicopathologic features of breast cancer. / Kalinina, Tatiana; Kononchuk, Vladislav; Alekseenok, Efim и др.
в: Journal of Personalized Medicine, Том 12, № 1, 4, 01.2022.Результаты исследований: Научные публикации в периодических изданиях › статья › Рецензирование
}
TY - JOUR
T1 - Associations between the levels of estradiol-, progesterone-, and testosterone-sensitive mirnas and main clinicopathologic features of breast cancer
AU - Kalinina, Tatiana
AU - Kononchuk, Vladislav
AU - Alekseenok, Efim
AU - Abdullin, Grigory
AU - Sidorov, Sergey
AU - Ovchinnikov, Vladimir
AU - Gulyaeva, Lyudmila
N1 - Funding Information: Acknowledgments: The work was performed using the equipment of the Center for Collective Use “Proteomic Analysis”, supported by funding from the Ministry of Science and Higher Education of the Russian Federation (agreement No. 075-15-2021-691). Funding Information: Funding: This research was funded by the Russian Science Foundation, grant number 19-15-00319. Publisher Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2022/1
Y1 - 2022/1
N2 - Despite the existing advances in the diagnosis and treatment of breast cancer (BC), the search for markers associated with the clinicopathological features of BC is still in demand. MiRNAs (miRs) have potential as markers, since a change in the miRNA expression profile accompanies the initiation and progression of malignant diseases. The receptors for estrogen, androgen, and progesterone (ER, AR, and PR) play an important role in breast carcinogenesis. Therefore, to search for miRNAs that may function as markers in BC, using bioinformatic analysis and the literature data, we selected 13 miRNAs whose promoter regions contain binding sites for ER or AR, or putative binding sites for ER, AR, and PR. We quantified their expression in MCF-7 cells treated with estradiol, progesterone, or testosterone. The levels of miRNAs sensitive to one or more of these hormones were quantified in BC samples (n = 196). We discovered that high expression levels of miR-190b in breast tumor tissue indicate a positive ER status, and miR-423 and miR-200b levels differ between patients with and without HER2 amplification. The miR-193b,-423,-190a,-324, and-200b levels were associated with tumor size or lymph node status in BC patients, but the presence of these associations depended on the status and expression level of ER, PR, HER2, and Ki-67. We also found that miR-21 expression depends on HER2 expression in ER-and/or PR-positive BC. The levels of miRNA were significantly different between HER2 0 and HER2 1+ tumors (p = 0.027), and between HER2 0 and HER2 2+, 3+ tumors (p = 0.005).
AB - Despite the existing advances in the diagnosis and treatment of breast cancer (BC), the search for markers associated with the clinicopathological features of BC is still in demand. MiRNAs (miRs) have potential as markers, since a change in the miRNA expression profile accompanies the initiation and progression of malignant diseases. The receptors for estrogen, androgen, and progesterone (ER, AR, and PR) play an important role in breast carcinogenesis. Therefore, to search for miRNAs that may function as markers in BC, using bioinformatic analysis and the literature data, we selected 13 miRNAs whose promoter regions contain binding sites for ER or AR, or putative binding sites for ER, AR, and PR. We quantified their expression in MCF-7 cells treated with estradiol, progesterone, or testosterone. The levels of miRNAs sensitive to one or more of these hormones were quantified in BC samples (n = 196). We discovered that high expression levels of miR-190b in breast tumor tissue indicate a positive ER status, and miR-423 and miR-200b levels differ between patients with and without HER2 amplification. The miR-193b,-423,-190a,-324, and-200b levels were associated with tumor size or lymph node status in BC patients, but the presence of these associations depended on the status and expression level of ER, PR, HER2, and Ki-67. We also found that miR-21 expression depends on HER2 expression in ER-and/or PR-positive BC. The levels of miRNA were significantly different between HER2 0 and HER2 1+ tumors (p = 0.027), and between HER2 0 and HER2 2+, 3+ tumors (p = 0.005).
KW - Biomarker
KW - Breast cancer
KW - Hormone-dependent car-cinogenesis
KW - Lymph node metastasis
KW - MicroRNA
UR - http://www.scopus.com/inward/record.url?scp=85121690450&partnerID=8YFLogxK
UR - https://www.elibrary.ru/item.asp?id=47549055
UR - https://www.mendeley.com/catalogue/5f644003-9637-36df-974f-f053f63bfdbe/
U2 - 10.3390/jpm12010004
DO - 10.3390/jpm12010004
M3 - Article
C2 - 35055320
AN - SCOPUS:85121690450
VL - 12
JO - Journal of Personalized Medicine
JF - Journal of Personalized Medicine
SN - 2075-4426
IS - 1
M1 - 4
ER -
ID: 35228202